Geode Capital Management LLC Buys 6,994 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Geode Capital Management LLC raised its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 2.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 246,262 shares of the company’s stock after acquiring an additional 6,994 shares during the period. Geode Capital Management LLC owned about 0.12% of Cellebrite DI worth $5,425,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. R Squared Ltd bought a new stake in shares of Cellebrite DI in the 4th quarter worth about $100,000. Polen Capital Management LLC acquired a new position in Cellebrite DI in the fourth quarter valued at about $222,000. Victory Capital Management Inc. bought a new stake in Cellebrite DI during the fourth quarter worth about $234,000. HighTower Advisors LLC acquired a new stake in shares of Cellebrite DI during the fourth quarter worth approximately $274,000. Finally, Pictet Asset Management Holding SA bought a new position in shares of Cellebrite DI in the fourth quarter valued at approximately $283,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Cellebrite DI Stock Up 0.4 %

Shares of CLBT opened at $19.64 on Friday. The stock’s fifty day simple moving average is $18.73 and its 200-day simple moving average is $20.11. The firm has a market capitalization of $4.70 billion, a PE ratio of -14.13, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a 12-month low of $10.25 and a 12-month high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last issued its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. Analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CLBT. JPMorgan Chase & Co. raised their price target on Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price target on shares of Cellebrite DI in a report on Wednesday, April 2nd. Finally, Lake Street Capital upped their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $23.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.